Crataegus oxycantha (Hawthorn) monograph

Alternative Medicine Review

Volumn 15, Issue 2, 2010, Pages 164-167

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BIOFLAVONOID; CITRININ; CRATAEGUS EXTRACT; PLACEBO; CARDIOVASCULAR AGENT; PLANT EXTRACT; PROTECTIVE AGENT;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CRATAEGUS OXYCANTHA; FLOWER; FRUIT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; NONHUMAN; PHYTOTHERAPY; PLANT LEAF; PLANT ROOT; REVIEW; ANIMAL; CRATAEGUS; EVIDENCE BASED MEDICINE; HEART FAILURE; METHODOLOGY;

ANIMALS; CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; CRATAEGUS; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; PHYTOTHERAPY; PLANT EXTRACTS; PROTECTIVE AGENTS;

EID: 77954626721     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Hobbs C, Foster S. Hawthorne - a literature review. Herbalgram 1990;22:19-33.
2. Duke JA. Handbook of Medicinal Herbs. Boca Raton, FL: CRC Press; 1985:146-147.
3. Mills S, Bone K. Principles and Practice of Phytotherapy: Modern Herbal Medicine. Edinburg, UK: Churchill Livingstone; 2000:439-447.
4. Weihmayr T, Ernst E. Therapeutic effectiveness of Crataegus. Fortschr Med 1996;114:27-29. [Article in German]
5. Vitamin P. http://www.thefreedictionary.com/ vitamin+P [Accessed April 5, 2010]
6. Jayalakshmi R, Thirupurasundari CJ, Devaraj SN. Pretreatment with alcoholic extract of Crataegus oxycantha (AEC) activates mitochondrial protection during isoproterenol-induced myocardial infarction in rats. Mol Cell Biochem 2006;292:59-67. (Pubitemid 44697400)
7. Swaminathan JK, Khan M, Mohan IK, et al. Cardioprotective properties of Crataegus oxycantha extract against ischemia-reperfusion injury. Phytomedicine 2010 Feb 17. [Epub ahead of print]
8. Schussler M, Holzl J, Fricke U. Myocardial effects of flavonoids from Crataegus species. Arzneimittelforschung 1995;45:842-845.
9. Weikl A, Assmus KD, Neukum-Schmidt A, et al. Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II). Fortschr Med 1996;114:291-296. [Article in German]
10. Popping S, Rose H, Ionescu I, et al. Effect of a hawthorn extract on contraction and energy turnover of isolated rat cardiomyocytes. Arzneimittelforschung 1995;45:1157-1161.
11. Blesken R. Crataegus in cardiology. Fortschr Med 1992;110:290-292. [Article in German]
12. Gabor M. Pharmacologic effects of flavonoids on blood vessels. Angiologica 1972;9:355-374.
13. Shanthi S, Parasakthy K, Deepalakshmi PD, Devaraj SN. Hypolipidemic activity of tincture of Crataegus in rats. Indian J Biochem Biophys 1994;31:143-146.
14. Rajendran S, Deepalakshmi PD, Parasakthy K, et al. Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet. Atherosclerosis 1996;123:235-241. (Pubitemid 26175078)
15. Tauchert M, Gildor A, Lipinski J. High-dose Crataegus extract WS 1442 in the treatment of NYHA stage II heart failure. Herz 1999;24:465-474. [Article in German]
16. Tauchert M. Efficacy and safety of Crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J 2002;143:910-915. (Pubitemid 34595353)
17. Holubarsch CJ, Colucci WS, Meinertz T, et al. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail 2008;10:1255-1263.
18. Rewerski W, Lewak S. Some pharmacological properties of flavan polymers isolated from hawthorn (Crataegus oxyacantha). Arzneimittelforschung 1967;17:490-491. [Article in German]
19. Uchida S, Ikari N, Ohta H, et al. Inhibitory effects of condensed tannins on angiotensin converting enzyme. Jpn J Pharmacol 1987;43:242-246. (Pubitemid 17233857)
20. Walker AF, Marakis G, Morris AP, Robinson PA. Promising hypotensive effect of hawthorn extract: a randomized double-blind pilot study of mild, essential hypertension. Phytother Res 2002;16:48-54. (Pubitemid 34116695)
21. Walker AF, Marakis G, Simpson E, et al. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial. Br J Gen Pract 2006;56:437-443.
22. Xu H, Xu HE, Ryan D. A study of the comparative effects of hawthorn fruit compound and simvastatin on lowering blood lipid levels. Am J Chin Med 2009;37:903-908.
23. Xie W, Sun C, Liu S. Effects of hawthorn flavanone on blood-fat and expression of lipogenesis and lipolysis genes of hyperlipidemia model mouse. Zhongguo Zhong Yao Za Zhi 2009;34:224-229. [Article in Chinese]
24. McGuffin M, Hobbs C, Upton R, Goldberg A. Botanical Safety Handbook. New York, NY: CRC Press; 1997:37.
25. Ammon HP, Handel M. Crataegus, toxicology and pharmacology, Part I: Toxicity. Planta Med 1981;43:105-120.
26. Blumenthal M, Busse W, Goldberg A, et al. The Complete German Commission E Monographs. Boston, MA: American Botanical Council; 1998:142-144.
27. Daniele C, Mazzanti G, Pittler MH, Ernst E. Adverse-event profile of Crataegus spp.: a systematic review. Drug Saf 2006;29:523-535.